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Abstract
Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic
diseases characterized by clonal hematopoiesis and hyperproliferation of
terminally differentiated myeloid cells. The disease is driven by somatic mutations
in exon 9 of CALR, exon 10 of MPL or JAK2-V617F in >90% of the cases,
while the remaining cases are termed "triple negative". We aimed to identify
the disease causing mutations in the triple negative cases of ET and PMF by
applying whole exome sequencing (WES) on paired tumor and control samples
from 8 patients. We found evidence of clonal hematopoiesis in 5/8 studied cases
based on clonality analysis and presence of somatic genetic aberrations. WES
identified somatic mutations in 3/8 cases. We did not detect any novel recurrent
somatic mutations. In 3 patients with clonal hematopoiesis, analyzed by WES, we
identified a somatic MPL-S204P and a germline MPL-V285E mutation, as well as
a germline JAK2-G571S variant. Sequencing of entire coding region of MPL a...
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Key points: 
 
- Activating mutations outside exon 10 of MPL were identified in 10% of 
triple negative cases of ET and PMF. 
- JAK2-V625F and JAK2-F556V were identified in two triple negative 
cases of ET and shown to activate JAK/STAT5 signaling.  
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Abstract 
 
 Essential thrombocythemia (ET) and primary myelofibrosis (PMF) are chronic 
diseases characterized by clonal hematopoiesis and hyperproliferation of terminally 
differentiated myeloid cells. The disease is driven by somatic mutations in exon 9 of 
CALR, exon 10 of MPL or JAK2-V617F in >90% of the cases, while the remaining 
cases are termed “triple negative”. We aimed to identify the disease causing 
mutations in the triple negative cases of ET and PMF by applying whole exome 
sequencing (WES) on paired tumor and control samples from 8 patients. We found 
evidence of clonal hematopoiesis in 5/8 studied cases based on clonality analysis 
and presence of somatic genetic aberrations. WES identified somatic mutations in 
3/8 cases. We did not detect any novel recurrent somatic mutations. In 3 patients 
with clonal hematopoiesis, analyzed by WES, we identified a somatic MPL-S204P 
and a germline MPL-V285E mutation, as well as a germline JAK2-G571S variant. 
Sequencing of entire coding region of MPL and JAK2 was performed in additional 62 
and 49 triple negative cases of ET or PMF, respectively. We detected new somatic 
(T119I, S204F, E230G, Y591D) and one germline (R321W) MPL mutation in 5/62 
cases. All the mutations were gain-of-function mutations when analyzed in functional 
assays. JAK2 variants were identified in 5/57 triple negative cases and 3 of them 
were germline. We could demonstrate that JAK2-V625F and JAK2-F556V are gain-
of-function mutations. Our results suggest that triple negative cases of ET and PMF 
do not represent a homogenous disease entity. Cases with polyclonal hematopoiesis 
might represent hereditary disorders.  
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Introduction 
Essential thrombocythemia (ET), primary myelofibrosis (PMF) and 
polycythemia vera (PV) are the classical BCR-ABL negative myeloproliferative 
neoplasms (MPN). They are chronic diseases, characterized by clonal expansion of 
differentiated myeloid cells driven by somatic mutations. Most of the cases are 
sporadic, however familial clustering has also been observed. In 95% of PV and 50-
60% of ET and PMF cases the disease is driven by an acquired mutation in the 
JAK2 gene - V617F1-4. JAK2-V617F leads to the constitutive activation of the JAK2 
kinase and subsequently the JAK/STAT signaling pathway. The remaining cases of 
PV carry mutations in exon 12 of JAK2. Although JAK2 mutations in MPN are 
acquired, in recent years several families with hereditary thrombocytosis (HT) have 
been described to have germline JAK2 mutations5-7. The second most commonly 
mutated gene in ET and PMF is CALR encoding calreticulin. Mutations in exon 9 of 
CALR have been described in 25% and 35% of patients with ET and PMF, 
respectively8,9. There is over 40 different CALR mutation types reported in the 
literature and they all result in a frameshift into alternative reading frame 1 of the last 
exon of CALR gene and hence the acquisition of a novel peptide at the C-terminus of 
the mutant protein8,9. The functional consequence of CALR mutations is not yet well 
understood, but the available data suggest that similar to JAK2 mutations, CALR 
mutations also lead to the activation of the JAK/STAT signaling pathway8. Besides 
JAK2 and CALR, a small proportion (5-10%) of ET and PMF patients carry somatic 
mutations in exon 10 of MPL, encoding the thrombopoietin receptor10,11. The most 
common mutation is W515L, however W515K, W515A, W515S, and others have 
been reported11,12. The mutations cluster in the intracellular juxtamembrane domain 
of the receptor, which prevents its activation in the absence of the ligand13. Germline 
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mutations in MPL have been associated with cases of HT. MPL S505N in exon 10 
was found in one family, although it was also reported as somatic in sporadic cases 
of ET12,14. Mutations in JAK2, CALR and MPL are usually mutually exclusive and 
account for >90% of ET and PMF cases8. However, in 12% of ET and 5% of PMF 
cases the disease driver is currently unknown and this group of patients is referred to 
as the triple negative. In clinical practice, the diagnostic work-up of these patients is 
limited to analyzing exons 14 of JAK2, exon 10 of MPL and exon 9 of CALR for the 
presence of mutations. Mutations in other genes such as TET2, ASXL1, and CBL 
have been described in all MPN patients, however they co-occur with JAK2, MPL 
and CALR mutations and are found across a variety of myeloid malignancies15-18. 
Most of these mutations were shown to be involved in establishing clonal 
hematopoiesis or disease progression.  
In this study we aimed to identify the disease causing mutation in triple 
negative cases of ET and PMF by applying whole exome sequencing (WES) 
primarily for the purpose of identifying somatic mutations. In cases where somatic 
mutations could not be identified, we looked for germline mutations that might be 
relevant for the phenotype. Finally we aimed to assess the functional consequence 
of identified mutations.    
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Methods 
Patient samples 
 The study included 79 patients diagnosed with ET (N=67) or PMF (N=12), 
followed at the Department of Hematology Oncology, Fondazione IRCCS Policlinico 
San Matteo, Pavia, Italy and the Medical University of Vienna, Vienna, Austria. All 
patients provided written informed consent in accordance with the Declaration of 
Helsinki and the study was approved by local ethics committees. Diagnostic criteria 
were applied as previously reported, and later revised3,19,20. Genomic DNA was 
isolated according to standard procedures from peripheral blood granulocytes, whole 
blood samples and immunomagnetically purified circulating T cells. JAK2, MPL and 
CALR mutation analyses were performed as previously described, and presence of 
these mutations was excluded in all patients included in the study8.  
 
Microarray analysis 
DNA samples were processed according to the manufacturer’s instructions 
and hybridized to Genome-Wide Human SNP 6.0 arrays (Affymetrix). The data was 
analyzed using Genotyping Console version 3.0.2 software (Affymetrix), by applying 
previously reported criteria for annotation21. The data has been deposited to the 
ArrayExpress database under E-MTAB-3778.  
 
Whole exome and Sanger sequencing  
 DNA libraries were generated from genomic DNA isolated from granulocytes 
and CD3+ T-lymphocytes using TruSeq DNA Sample Prep-Kit v2 (Illumina) with 
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TruSeq Exome Enrichment Kit (Illumina) and Nextera Rapid Capture Exome kit 
(Illumina) according to the manufacturer’s instructions. Sequencing was performed 
using the Illumina HiSeq 2000 platform, the 51-bp or 100-bp paired-end configuration 
and Illumina v3 reagents. Data analysis is described in Supplemental Methods. 
 Sanger sequencing was performed as described previously8. Details and 
primer sequences are listed in the Supplemental methods.  
 
X-inactivation based clonality assay 
 Clonal analysis of hematopoietic cells was performed through the study of 
methylation pattern and allelic expression of HUMARA, PGK and IDS genes on 
peripheral blood granulocytes, whereas T lymphocytes were used as a control 
tissue, as previously described22. 
 
Functional analysis of identified mutations 
 Methods used for generation of cDNA constructs, virus production and 
transduction, cell proliferation and viability assays performed in Ba/F3 cells and 
Western blotting are described in Supplemental Methods. Details of the luciferase 
assay performed in γ2A cells are also described in Supplemental Methods.    
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Results  
 
Whole exome sequencing identifies novel mutations in triple negative PMF and 
ET 
 To identify disease driving mutations in triple negative MPN we selected 4 
cases of ET and 4 cases of PMF in which mutations in MPL exon 10, CALR exon 9 
and JAK2-V617F were excluded, as previously reported8. Whole exome sequencing 
(WES) was performed, in all 8 cases, on the DNA samples from granulocytes and T-
cells, which were considered as the tumor and the control tissue, respectively. 
Median number of 104,713,153 unique reads per sample was obtained, which 
resulted in median coverage of 110x across all target regions. The variants identified 
in the tumor tissue were annotated for functional consequence and several filtering 
criteria were applied, including subtraction of variants present in the control tissue, in 
order to detect potential somatic mutations (Supplemental Methods). Candidate 
somatic mutations were validated using Sanger sequencing on samples from both 
tissues, to exclude false positive and insufficiently covered germline variants. Using 
this approach we identified somatic mutations in 3/8 patients. Two patients 
diagnosed with PMF carried 10 somatic mutations each, while 2 somatic mutations 
were found in one patient with ET (Figure 1A). In both PMF patients we identified 
mutations in genes known to be relevant for myeloid malignancies, CBL, TET2, 
ASXL1, SRSF2, including a somatic mutation affecting the thrombopoietin receptor – 
MPL-S204P. We did not detect any recurrent novel somatic mutations in the 8 
studied patients. 
 As in 5/8 patients we did not detect a single somatic mutation by WES, we 
analyzed the WES data for the presence of germline mutations in genes involved in 
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MPN pathogenesis, by applying the same filtering criteria as described for analysis 
of somatic mutations, except for the subtraction of variants present in the control 
tissue (Supplemental Methods). In one PMF patient we identified a germline 
mutation in MPL-V285E and validated it by Sanger sequencing. In the ET patient 
with two identified somatic mutations we detected and validated a germline variant in 
JAK2-G571S (Figure 1A). The germline mutations in MPL and JAK2 were not 
annotated as common variants in any of the databases we used for the analysis of 
the WES data. 
 Granulocyte DNA samples of the 8 selected patients were, in addition to 
WES, analyzed for acquired chromosomal copy number alterations and uniparental 
disomies (UPD) using genome-wide SNP microarrays. Due to DNA quality the data 
was obtained for 7/8 cases. We identified a somatic UPD of chromosome 6p in one 
patient with PMF (Supplemental Figure 1) and a gain on chromosome 4q in a patient 
with ET. The patient with 6p UPD carried a germline MPL-V285E mutation and no 
detectable somatic mutations, while the ET patient with 4q gain carried the 2 
validated somatic mutations in ITGAV and WBSCR28 (Figure 1A).  
 Chromosomal aberrations often target genomic regions that carry the genes 
relevant for the disease. We integrated the microarray data from additional 20 triple 
negative MPN patients, with the microarray and WES data from the 8 patients 
described above, however we did not identify any somatic mutations in the regions 
affected with chromosomal aberrations (Figure 1B). Chromosomal aberrations were 
detected in 5/20 cases, suggesting that the disease is clonal in at least 25% of the 
cases. UPD of chromosome 6p was observed in 2 cases, however the target gene 
remains unknown. 
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 As 3/8 patients studied by WES and microarrays were female, we performed 
X-inactivation based clonality analysis. Clonal hematopoiesis was observed in one 
PMF case, polyclonal pattern in one ET case, while in the second case of ET the 
patient was not informative at the analyzed loci. Taking results of WES, microarray 
analysis and clonality assay in consideration we have found evidence of clonal 
hematopoiesis in 5/8 triple negative MPN patients (4/4 with PMF and 1/4 with ET) 
included in the study, suggesting that the disease might be polyclonal in the other 3 
cases. Two triple negative MPN patients carried mutations affecting the extracellular 
domain of the thrombopoietin receptor, in contrast to the previously reported 
mutations, which cluster in the juxtamembrane domain encoded by exon 10 of the 
MPL gene.        
 
Targeted sequencing of all coding exons of MPL and JAK2 genes 
 To determine the frequency of the MPL mutations outside of exon 10, in triple 
negative MPN patients, we performed Sanger sequencing of all coding exons of 
MPL on samples from an additional cohort of 61 triple negative MPN cases (53 
patients with ET and 8 patients with PMF). Variants outside exon 10 of MPL were 
identified in 5/61 cases. The control tissue was available for 4 patients and we could 
determine the origin of identified mutations. MPL-T119I, MPL-S204F and MPL-
E230G were somatic mutations (Figure 2A), while MPL-R321W was germline 
(Figure 2B). We identified a second triple negative case with the MPL-S204P 
mutation and diagnosis of ET, however the control tissue was not available. The 
same mutation was confirmed to be somatic in the PMF case subjected to WES 
(Figure 2A). We also detected a variant R321Q in one case of triple negative ET, 
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however this variant was reported with a variant frequency of 3% in East Asian 
population in the 1000 Genomes project, and therefore was not considered further 
for functional analysis.  
Mutations outside exon 10 of MPL were identified in 7/69 cases of triple 
negative MPN (Figure 2A-B). All mutations affect the extracellular domain of the 
thrombopoietin receptor (Figure 2D). 
In addition to these 61 cases, we performed targeted sequencing of all coding 
exons of MPL in a case of ET, which was initially diagnosed as JAK2 and MPL 
negative, but developed a JAK2-V617F positivity 5.5 years following the diagnosis. 
We tested the diagnostic sample for CALR mutations, however it was negative. 
When we sequenced the entire coding region of MPL we identified a somatic MPL-
Y591D mutation in the diagnostic sample (Figure 2A), which remained throughout 
the 5.5 years follow-up. Since the clinical data indicates that the MPL-Y591D 
mutation was sufficient to cause the phenotype at diagnosis we included this 
mutation for the functional validations.   
 As WES revealed a germline JAK2-G571S mutation in one of the triple 
negative MPN patients, we performed Sanger sequencing for all coding exons of 
JAK2 on DNA samples from additional 49 triple negative MPN patients (41 patients 
with ET and 8 with PMF). We identified variants in JAK2 in 4/49 analyzed cases. All 
patients with JAK2 variants were diagnosed with ET. JAK2-G335D and JAK2-V625F 
were confirmed as germline mutations, while the control tissue was not available 
from patients with JAK2-F556V and a second case of JAK2-G571S (Figure 2C, E). 
Mutations affecting exons 8, 13 and 15 of JAK2 gene were identified in total of 5/57 
triple negative MPN cases.  
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 Clonality analysis was performed for 23/39 female patients included for 
targeted sequencing of both MPL and JAK2. Clonal hematopoiesis was revealed in 3 
cases, while 10 cases were polyclonal and 10 cases were either non-informative or 
showed an ambiguous result of the analysis. In regard to patients with germline 
mutations, patient carrying JAK2-V625F was not informative, while patient with MPL-
R321W had clonal hematopoiesis. Other patients with germline mutations (JAK2-
G335D, JAK2-G571S and MPL-V285E) were male. All the patients with germline 
MPL and JAK2 mutations where considered as sporadic as the family history was 
either negative for presence of MPN phenotype in family members, or unavailable.   
 
Functional analysis of identified MPL and JAK2 mutations  
 We next performed functional assays to determine whether the identified MPL 
mutants were able to induce ligand-independent JAK-STAT signaling, similar to 
other pathogenic mutants such as S505N and W51523. We employed a luciferase 
reporter assay in JAK2-deficient gamma 2A cells where we transiently expressed the 
cDNAs for wild type or mutant MPL, JAK2, STAT5, the STAT5 reporter Spi-Luc and 
pRL-TK for transfection control23. As shown in Figure 3A expression of MPL mutants 
supported cytokine-independent JAK2-STAT5 signaling. Of interest, detection of 
activity required longer times (48h) than for the usual pathogenic mutants W515K or 
S505N, which exhibit constitutive activity at 24h post-transfection23. This data 
suggests that the identified mutations have a milder effect compared to the common 
W515K mutant.  
 To further study the functional consequence of MPL mutations we expressed 
the MPL wild type or mutants in the interleukin-3-dependent murine cell line Ba/F3. 
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To test how the expression of MPL mutants affects proliferation of Ba/F3 cells, we 
performed a starvation assay for 72h (Figure 3B). None of the mutants conferred 
cytokine independent growth of Ba/F3 cells or hypersensitivity to IL-3, except for the 
W515K which was used as a positive control (Figure 3B-C and Supplemental Figure 
2A). Since most of the mutations clustered in the extracellular domain of the 
thrombopoietin receptor, we tested the cell viability in the dilution series of TPO to 
determine whether the mutations confer hypersensitivity to TPO (Figure 3D and 
Supplemental Figure 2B). We did not observe a difference between the cells 
expressing the mutants affecting the extracellular domain of MPL compared to the 
wild type. However, Ba/F3 cells expressing MPL-Y591D showed marked 
hypersensitivity to TPO. To confirm that the MPL-Y591D mutation gives proliferative 
advantage to the Ba/F3 cells, we performed a competition assay in which the cells 
expressing MPL wild type (pMSCV-HA-MPLwt-puro) were mixed in 4:1 ratio with 
cells expressing MPL-Y591D and GFP (pMx-IRES-HA-MPLY591D-GFP). We 
assessed the GFP positivity by flow cytometry analysis at day 0, 3 and 6. In two 
independent biological replicates we could show that the GFP positivity of mixed 
culture reaches 60% in the presence of 1ng/mL of TPO in 6 days, meaning that 
expression of MPL-Y591D confers proliferative advantage in vitro (Figure 3F and 
Supplemental Figure 2D). The effect on proliferation was lower than the one 
observed for MPL-W515K, and also absent when the cells were cultured in the 
presence of IL-3 (Figure 3E and Supplemental Figure 2C).  
 The functional data suggests that all identified MPL mutations are gain-of-
function mutations, leading to the activation of JAK2-STAT5 signaling. MPL-Y591D 
is the only mutation which gives an obvious but mild proliferative advantage to the 
cells in vitro.  
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 We employed the luciferase reporter assay in JAK2-deficient gamma 2A cells 
to assess the ligand-independent JAK-STAT5 signaling activation of identified JAK2 
mutants in the presence of MPL (Figure 4A) and EPOR (Supplemental Figure 3A)23. 
Only the expression of JAK2-V625F supported cytokine-independent JAK2-STAT5 
signaling in the presence of MPL, while no difference was observed for other 
mutants compared to the wild type. Upon expressing all the JAK2 mutants or the wild 
type in Ba/F3-MPL cells, we tested the cell viability in the serial dilution of IL-3 and 
TPO concentrations. The cells expressing JAK2-V625F showed hypersensitivity to 
both IL-3 and TPO (Figure 4B-C, Supplemental Figure 3B-C), while for JAK2-F556V 
expressing cells we could also observe hypersensitivity to TPO. In addition we 
examined the phosphorylation of STAT5 in the absence of cytokine in the 
transfected cell lines. We detected increased phosphorylation of STAT5 in the 
absence of cytokines in the cells expressing JAK2-V625F and JAK2-F556V (Figure 
4D). Thus, increased activation of JAK-STAT signaling is likely responsible for the 
hypersensitivity to TPO observed for the two mutants.   
For personal use only.on November 3, 2015. by guest  www.bloodjournal.orgFrom 
16 
 
Discussion  
 
 We identified somatic and germline mutations outside exon 10 of MPL in 
10.1% (7/69) cases of triple negative ET and PMF. Somatic mutations of MPL at 
positions T119I, S204F, S204P and E230G were detected in exons 3, 4 and 5, 
respectively, while germline mutations V285E and R321W were affecting exon 6 of 
MPL.  In one additional triple negative case of ET we identified a somatic mutation in 
exon 12 of MPL, MPL-Y591D, at diagnosis, however the patient became JAK2-
V617F positive in a 5.5 year follow-up. Germline mutations of the JAK2 at positions 
G335D, G571S and V625F, and mutation of unknown origin F556V in exons 8, 13 
and 15 of JAK2 were found in 8.8% (5/57) cases of triple negative ET and PMF. All 
mutations were heterozygous. Taken together, non-canonical mutations (outside of 
exons usually examined for diagnostic purposes) of MPL and JAK2 are present in 
about 18.9% of triple negative MPN cases. We could demonstrate that all identified 
MPL mutations lead to constitutive activation of JAK/STAT5 signaling, and that MPL-
Y591D provides proliferative advantage to Ba/F3 cells. We could demonstrate that 
JAK2-V625F is a gain-of-function mutation, while for F556V we found evidence of 
constitutive activation of JAK/STAT5 signaling by Western immunodetection. 
However, the other JAK2 mutants do not significantly influence the JAK/STAT5 
signaling in the presence of EPOR or MPL in vitro.  
 Mutations outside exon 10 of MPL have previously been reported in the 
literature, but their origin was not determined mainly due to lack of control tissue 
availability. MPL-S204F mutation associated with chromosome 1p UPD and 
heterozygous MPL-S204P mutation have previously been identified in two JAK2-
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V617F negative PMF cases24,25, while MPL-Y591D was reported in a JAK2-V617F 
positive PV patient with chromosome 1p UPD24. In all three cases the control tissue 
was not available, and the functional relevance of the mutations was not shown. We 
could demonstrate that somatic MPL-Y591D mutation was present at diagnosis in a 
triple negative ET patient who during follow-up acquired JAK2-V617F. Hitchcock et 
al. have shown that MPL-Y591 is a part of the YRRL motif (Figure 2A), that through 
interaction with AP2 regulates surface expression and degradation of MPL upon 
stimulation26. In the same study the authors showed that cells expressing MPL-
Y591F have a proliferation advantage and an increased JAK2, STAT5 and AKT 
activation upon stimulation26. It is unclear why MPL-Y591D is found together with 
JAK2-V617F. Further studies will be necessary to determine whether combination of 
these mutations has a specific effect on the patient’s phenotype. 
 Germline MPL mutations have been reported in cases of HT. Clinical features 
of ET and HT are similar and that is why some of the HT cases could be diagnosed 
as sporadic ET especially if the family history is unknown or absent. The differences 
in the biology of the two diseases are mainly that HT exhibit polyclonal 
hematopoiesis, lack somatic mutations and have generally better prognosis without 
disease progression27. The first germline MPL mutation associated with HT was 
S505N in exon 10, which was also reported as somatic in sporadic ET12,14. MPL-
Y252H mutation was reported in a pediatric case of ET with clonal hematopoiesis 
without evidence of the mutation origin28, while P106L was reported as homozygous 
in several Arabic families with HT29. In our cohort, two activating germline mutations 
were identified in cases initially diagnosed as PMF (V285E) and ET (R321W). We 
cannot exclude the possibility that these mutations could have been acquired in 
common progenitors, as the only available germline control was DNA isolated from 
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T-cells. Both patients had clonal hematopoiesis, as detected by presence of acquired 
UPD of chromosome 6 in patient with PMF (Supplemental Figure 1) and X-
inactivation based clonality assay in the patient with ET. We can only speculate that 
MPL-V285E and MPL-R321W are either not sufficient to cause the observed 
phenotypes and that an additional event is necessary, likely the target of 6p 
aberration in the case with PMF, as we did not detect any other somatic mutations in 
this patient, or that the 6p aberration and presence of clonal hematopoiesis are 
associated with disease progression.  
 The four somatic mutations we identified were affecting the extracellular 
ligand binding domain of the MPL30,31, while the two germline mutations affected the 
membrane proximal extracellular domain which appears to play a role in negative 
regulation of receptor activation. We initially hypothesized that the mutations might 
affect the affinity to TPO, however, the luciferase assay we performed in gamma 2A 
cells showed that all identified mutants activated STAT5 induced transcription in the 
absence of stimulation with TPO. 
 Triple negative status of patients with PMF was shown to associate with 
inferior overall and leukemia-free survival32, however in 2/12 triple negative PMF 
patients with novel mutations identified in our study, MPL-S204P and MPL-V285E, 
we did not observe disease progression or leukemic transformation in a 12-year and 
6-year follow-up, respectively. Although the number of patients is too low to perform 
statistical analyses, the clinical data indicates that these patients might have a better 
clinical course, in accordance with our molecular and functional findings. Analysis of 
larger patient cohorts will be necessary to confirm the effect of non-canonical MPL 
mutations on patients’ prognosis.  
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 Germline JAK2 mutations clustering in the pseudokinase or kinase domain 
have been reported in several families with HT5-7. In all cases, they were weak gain-
of-function mutations. Here we reported 4 different JAK2 mutations in 5 triple 
negative ET cases. For JAK2-V625F and JAK2-F556V we could demonstrate that 
they are gain-of-function mutations leading to increased phosphorylation of STAT5 
and hypersensitivity to TPO. JAK2-G571S was found in 2 patients. In one case we 
had evidence for presence of somatic mutations identified by WES and a gain of 
chromosome 4q, indicating a clonal disease. JAK2-G571S was previously reported 
in a CALR positive patient with ET, and the lack of any hematological phenotype in 
family members carrying JAK2-G571S indicated that this mutation might be a 
polymorphism not relevant for the disease33. We did not find evidence for G571S and 
G335D mutations altering the function of JAK2. These JAK2 variants either do not 
play a role in the disease pathogenesis or require additional genetic events to exert a 
phenotype.  
 We cannot exclude that some of the patients with wild type MPL and JAK2, as 
determined by Sanger sequencing, might carry low burden mutations in these genes, 
as sensitivity of this method is estimated to ≥10%. Our data indicate that inclusion of 
all coding exons of JAK2 and MPL in the targeted sequencing panels designed for 
next-generation sequencing based approaches for detection of mutations, which are 
likely to enter the clinical practice in near future, is recommended. Analysis of bigger 
patient cohorts using such panels will provide more accurate estimation of the 
frequency of the non-canonical MPL and JAK2 mutations in triple negative MPN, and 
their relevance for diagnostic purposes.  
 In the rest of the cases studied by WES we did not identify a causative 
mutation due to absence of recurrent mutations. Similar results were obtained by 
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other groups34,35, who reported clonal hematopoiesis in 10/17 of the cases, similar to 
our study (evidence of clonality in 5/8 patients). The cases with polyclonal 
hematopoiesis are likely to be hereditary MPN-like disorders. The lack of recurrency 
and the fact that in one female PMF patient with clonal hematopoiesis we did not 
identify any somatic mutations, can be attributed to the limitations of the WES 
approach, which can only detect mutations in the coding exons of genes. RNA 
sequencing for detection of fusion oncogenes and whole genome sequencing for 
covering the regulatory sequences in the genome might provide an answer to which 
mutations drive the disease in the remaining triple negative MPN cases and whether 
they represent a heterogeneous disease entity.   
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Figure legends 
 
Figure 1. Overview of genetic aberrations identified in 28 patients with triple 
negative essential thrombocythemia or primary myelofibrosis. (A) Genetic 
findings from 4/8 studied patients, in which somatic genetic aberrations were 
identified using whole exome sequencing or microarray analysis. Somatic mutations 
are marked in black and germline mutations in blue. (B) Genomic overview of 
somatic mutations identified in 8 patients analyzed by whole exome sequencing and 
chromosomal aberrations found in 28 patients, detected with Affymetrix Genome-
Wide Human SNP 6.0 microarrays. The position and size of the colored bars indicate 
the chromosomal aberrations. Red bars depict deletions, blue uniparental disomies 
and green gains. ET, essential thrombocythemia; PMF, primary myelofibrosis; UPD, 
uniparental disomy. 
 
Figure 2. Mutations outside exon 10 of MPL and exons 12 and 14 of JAK2 
identified in triple negative essential thrombocythemia (ET) and primary 
myelofibrosis (PMF). (A) Somatic mutations in MPL identified in 4 cases of ET and 
one case of PMF. A common polymorphism is marked with the blue triangle. (B) 
Germline mutations in MPL identified in single cases of ET and PMF. (C) Germline 
JAK2 mutations found in 3 cases of triple negative ET. Red boxes in (A), (B) and (C) 
represent the amino acid change and black arrows indicate mutated bases. PT, 
patient; Ref, reference; GRN, granulocytes. (D) Schematic representation of the 
thrombopoietin receptor and the positions of mutations identified in triple negative ET 
and PMF. Somatic mutations are indicated in red. (E) Schematic representation of 
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the JAK2 kinase and the mutations found in ET. Black stars in (D) and (E) indicate 
positions of MPL W515K and JAK2 V617F, respectively.   
 
Figure 3. Functional analysis of MPL mutants. (A) STAT dependent 
transcriptional activity induced by wild type MPL or mutants of MPL. Gamma 2A cells 
which are JAK2-deficient were transiently transfected with wild type MPL (or 
mutants), JAK2, STAT5 and with Firefly STAT5 luciferase reporter spi-Luc and pRL-
TK vector coding for renilla luciferase. Luminescence was measured 48 h after 
transfection. After transfection medium was changed after 5h and replaced either 
with culture medium or medium supplemented with Tpo (10 ng/mL). Shown are 
average units + SEM of one representative experiment performed in triplicate out of 
three. ** P<.001; * P<.05. (B) Number of viable Ba/F3 cells expressing wild type MPL 
or different MPL mutants, in the absence of interleukin-3, was measured every 24h 
for 72h. The data is shown as average of two biological replicates performed each in 
triplicate ± SEM. (C-D) The viability of Ba/F3 cells expressing wild type MPL or 
different mutants was assessed after 72h in the presence of increasing 
concentrations of interleukin-3 (C) and thrombopoietin (D). Error bars represent 
SEM. (E-F) Ba/F3 cells expressing wild type MPL (MPL wt-puro) but not GFP were 
mixed with Ba/F3 cells expressing either wild type MPL (MPL wt-GFP), MPL Y591D 
(MPL Y591D-GFP) or MPL W515K (MPL W515K-GFP) and GFP in the 4:1 ratio and 
cultured in the presence of 1ng/mL interleukin-3 (E) or 1ng/mL thrombopoietin (F). 
The GFP positivity of the mixed culture was assessed every 72h by flow cytometric 
analysis. The experiment was performed in triplicate, with error bars representing 
SEM. SEM, standard error of the mean.     
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Figure 4. Functional analysis of JAK2 mutants. (A) STAT dependent 
transcriptional activity induced by wild type JAK2 or mutants of JAK2. Gamma 2A 
cells which are JAK2-deficient were transiently transfected with wild type JAK2 (or 
wild type JAK2 and mutant JAK2 in 1:1 ratio to represent heterozygous condition), 
MPL, STAT5 and with Firefly STAT5 luciferase reporter spi-Luc and pRL-TK vector 
coding for renilla luciferase. Luminescence was measured 24h after transfection. 
After transfection medium was changed after 5h and replaced either with culture 
medium or medium supplemented with Tpo (10 ng/mL). Shown are means ± 
standard error of the mean of 3 independent experiments done in triplicate. ** 
P<.001; * P<.05. (B-C) The viability of Ba/F3 cells expressing wild type MPL together 
with wild type JAK2 or different mutants was assessed after 72h in the presence of 
increasing concentrations of interleukin-3 (B) and thrombopoietin (C). Error bars 
represent SEM. (D) The activation of STAT5 in starving condition. Ba/F3 cells 
expressing the wild type MPL only, or together with wild type JAK2 or JAK2 mutants 
were cultured for 48h on TPO (1ng/mL) and then starved for 4 hours in serum free 
medium without TPO. Western blot was performed on the cell lysates with antibodies 
against pYSTAT5, STAT5, HA, and JAK2. An antibody against Hsc70 was used as 
loading control. 
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